Spots Global Cancer Trial Database for Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®
Official Title: Biomarker Analyses in Hepatocellular Carcinoma Patients Treated With Therasphere®
Study ID: NCT03203837
Conditions
Interventions
Study Description
Brief Summary: To analyze specific angiogenic, inflammatory and immune profiles in hepatocellular carcinoma patients who undergo radioembolization.
Detailed Description: Patients who have planned lobar radioembolization (TheraSphere (TS)) and consent to this study will have peripheral blood samples collected pre-TS, post-TS, 4 hours post-TS, 24 hours post-TS, 3 days post-TS, 7 days post-TS and 30 days post-TS to analyze specific angiogenic, inflammatory and immune profiles.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Northwestern University, Chicago, Illinois, United States
Contact Details
Name: Robert Lewandowski, MD
Affiliation: Northwestern University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
